Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 74 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEC2Olkh|ryP M3;JVnNCVkeHUh?=
MV-4-11 NXTrO4FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK4[ZNKSzVyPUCuNFE2QDZizszN M4S4OnNCVkeHUh?=
NKM-1 NXPUWYJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjie45KSzVyPUCuNFE3QTlizszN M4ewNXNCVkeHUh?=
ML-2 NVTJOGhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj0U|ZSUUN3ME2wMlAyQTh|IN88US=> M{\2THNCVkeHUh?=
BV-173 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzxdWZKSzVyPUCuNFI{OTRizszN NInObWVUSU6JRWK=
RS4-11 NWrkZ|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEK1PFch|ryP NFj3XYxUSU6JRWK=
HL-60 NIDEN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnNTWM2OD1yLkCyPVA5KM7:TR?= NFLZPI1USU6JRWK=
KY821 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHuUIJzUUN3ME2wMlAzQTd3IN88US=> M3[zSHNCVkeHUh?=
ECC10 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLBSFZDUUN3ME2wMlA{Pzl{IN88US=> MnL1V2FPT0WU
NCI-H720 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMESwNVEh|ryP M{ezS3NCVkeHUh?=
QIMR-WIL MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzp[mJPUUN3ME2wMlA1Ojh5IN88US=> NYHNRnRsW0GQR1XS
KG-1 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvZTWM2OD1yLkC0OFg3KM7:TR?= MmXvV2FPT0WU
TGW NIGxeoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLKVWxMUUN3ME2wMlA1PjN|IN88US=> NGHVWW9USU6JRWK=
ATN-1 NF7iO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTsTWM2OD1yLkC0O|M{KM7:TR?= MWnTRW5ITVJ?
RH-18 NFi1dW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\3UWlEPTB;MD6wOlA1QCEQvF2= NUn6WlVvW0GQR1XS
EW-18 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwME[4OFEh|ryP MVnTRW5ITVJ?
NB17 M4HlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH4W4pKSzVyPUCuNFcyOjRizszN MmLUV2FPT0WU
SK-NEP-1 M2X4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT4TWM2OD1yLkC3NlE{KM7:TR?= MWjTRW5ITVJ?
P12-ICHIKAWA NWi0T3ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTQc|ZWUUN3ME2wMlA4Pzd6IN88US=> MV\TRW5ITVJ?
KARPAS-45 M1vnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NISzdVBKSzVyPUCuNFc5OTVizszN MV\TRW5ITVJ?
EW-3 NIHPfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEiwOVMh|ryP NHXRSWhUSU6JRWK=
NB13 M2[yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfqT5ZKSzVyPUCuNFgzODNizszN M3XzUnNCVkeHUh?=
NCI-H209 NGiy[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTLS3BjUUN3ME2wMlA5PzB2IN88US=> NEC2SGtUSU6JRWK=
NCI-H1092 NECwNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXji[WJuUUN3ME2wMlExOjd3IN88US=> MVrTRW5ITVJ?
NH-12 NInt[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe1WWtwUUN3ME2wMlExPzR2IN88US=> MXTTRW5ITVJ?
697 NIPKe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrEXHNQUUN3ME2wMlExQDN7IN88US=> MlfBV2FPT0WU
KE-37 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnOTWM2OD1yLkGxN|ch|ryP NHjRUGhUSU6JRWK=
MOLT-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMUWxOlkh|ryP NF:4WFZUSU6JRWK=
CHP-134 Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH4TWM2OD1yLkG2N|A3KM7:TR?= MVzTRW5ITVJ?
D-283MED M1i4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TvcmlEPTB;MD6xO|Y5PiEQvF2= MX7TRW5ITVJ?
LU-135 NV:xVpkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L5ZWlEPTB;MD6xPFU2OiEQvF2= NETZVGZUSU6JRWK=
LU-134-A M{TVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMUi2O|Eh|ryP M2nwbHNCVkeHUh?=
EM-2 NFvwW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL5XYhKSzVyPUCuNVk6OThizszN NEXneFdUSU6JRWK=
LU-139 NGHRVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPjTWM2OD1yLkKwOFk5KM7:TR?= M{PUZnNCVkeHUh?=
ALL-PO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H1TGlEPTB;MD6yNVk5QCEQvF2= NHHGO5ZUSU6JRWK=
NB12 MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTkTWM2OD1yLkKzNVE2KM7:TR?= NVrmd49OW0GQR1XS
KP-N-YN MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDyU2pmUUN3ME2wMlI{PTd|IN88US=> NFrETppUSU6JRWK=
BEN NVv0UIN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ntRWlEPTB;MD6yN|k3QCEQvF2= Mn;rV2FPT0WU
HCC1569 M1HoUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vyOmlEPTB;MD6yOVExPiEQvF2= M2TPdXNCVkeHUh?=
HuO9 NUXWZVBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnnZWlKSzVyPUCuNlY4OTVizszN MXXTRW5ITVJ?
WM-115 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMke3N|gh|ryP MXnTRW5ITVJ?
CCRF-CEM MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPLTWM2OD1yLkOzOVI6KM7:TR?= NFm5WVVUSU6JRWK=
IST-SL1 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHuTWM2OD1yLkO1N|Q{KM7:TR?= MoXBV2FPT0WU
BE-13 M1TreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwM{[0OVkh|ryP NUDrUYNSW0GQR1XS
COR-L88 NX;DNFMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjLboRKSzVyPUCuN|Y2PCEQvF2= MXXTRW5ITVJ?
DOHH-2 MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwNEGwNlMh|ryP M1\lVHNCVkeHUh?=
A704 MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\3TWM2OD1yLkSyOlch|ryP MlrkV2FPT0WU
KNS-81-FD M{\jZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rnOGlEPTB;MD60OFAyPyEQvF2= M2j4[XNCVkeHUh?=
RPMI-8226 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LwXGlEPTB;MD60OVY2OiEQvF2= MoPuV2FPT0WU
TGBC24TKB M2\jN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP1R5pWUUN3ME2wMlQ2Pzd6IN88US=> MUDTRW5ITVJ?
NCI-H1304 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33SZ2lEPTB;MD60OlE2PyEQvF2= NEDQcHhUSU6JRWK=
MOLT-13 NYTtZ|VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHTWJJKSzVyPUCuOFY3OTNizszN MmXGV2FPT0WU
EW-22 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPXXWJtUUN3ME2wMlQ3PjdzIN88US=> MljlV2FPT0WU
MS-1 NVO1WVBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG0VXVKSzVyPUCuOFY6OzNizszN NFTPRWFUSU6JRWK=
RMG-I M{G0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK4TWM2OD1yLkS5OFY1KM7:TR?= Moq5V2FPT0WU
NTERA-S-cl-D1 NHrWXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNUCwNVkh|ryP Mk\FV2FPT0WU
NCI-H1048 M1\VRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iybmlEPTB;MD61NFk2OyEQvF2= NFXX[YRUSU6JRWK=
SW1417 M3XkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjYdY5HUUN3ME2wMlU2PDN6IN88US=> M2DyWXNCVkeHUh?=
DB MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvWbpVKSzVyPUCuOVcxQCEQvF2= MXzTRW5ITVJ?
MEG-01 MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID1OYxKSzVyPUCuOVg{OiEQvF2= MYTTRW5ITVJ?
EW-13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzRTWM2OD1yLkW4N|QyKM7:TR?= NYTabm9GW0GQR1XS
LAMA-84 NEnJXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK0TWM2OD1yLkW5NlA4KM7:TR?= M2PObXNCVkeHUh?=
J-RT3-T3-5 NX;NflhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknFTWM2OD1yLk[wPFA5KM7:TR?= M13YeHNCVkeHUh?=
MOLT-16 NYS4cmE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3joWmlEPTB;MD62OVI3PCEQvF2= Mn[xV2FPT0WU
DU-4475 NW\hU3E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzWcYpKSzVyPUCuOlU1OjdizszN NIPiXZlUSU6JRWK=
HAL-01 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO3TWM2OD1yLkeyOVQ6KM7:TR?= NHy0d2RUSU6JRWK=
RD NG\HWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\GN2lEPTB;MD63OVg6QSEQvF2= NWm1N3RKW0GQR1XS
OAW-28 M2rRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3DTWM2OD1yLke4N|ch|ryP MkjNV2FPT0WU
HCC38 M{DzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3iRm9KSzVyPUCuPFAyQSEQvF2= MVfTRW5ITVJ?
NMC-G1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\sTWM2OD1yLkixNVIyKM7:TR?= MlrMV2FPT0WU
EW-16 NI\DS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXKTWM2OD1yLkixN|I5KM7:TR?= MkTiV2FPT0WU
DU-145 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHXV5pKSzVyPUCuPFk6OjNizszN NIDibWNUSU6JRWK=
HPAF-II MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfBTWM2OD1yLkmyOlI5KM7:TR?= NFnWXZlUSU6JRWK=
A427 NHfTT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3Pc|RzUUN3ME2wMlk{ODJ{IN88US=> M1rsPXNCVkeHUh?=
PA-1 M1ryNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;FTWM2OD1yLkm1OlQzKM7:TR?= MVPTRW5ITVJ?
OAW-42 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CwPGlEPTB;MD65OlE1PiEQvF2= MkS4V2FPT0WU
L-428 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XSR2lEPTB;MT6wNVI2KM7:TR?= M{i1[XNCVkeHUh?=
COLO-824 NIHsXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwMEG3NFgh|ryP M4XmTnNCVkeHUh?=
P30-OHK M2njT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\hRmdqUUN3ME2xMlA1Pjh6IN88US=> NIrQU|lUSU6JRWK=
NCI-H2170 NHHC[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwME[yN{DPxE1? NVXVSJV4W0GQR1XS
HCC2998 M2PqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S1T2lEPTB;MT6wO|E{PSEQvF2= NIXzfXdUSU6JRWK=
NB14 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PEemlEPTB;MT6xN|c1QCEQvF2= MWfTRW5ITVJ?
TGBC1TKB NVHaO5FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;6dVhKSzVyPUGuNVQyPTJizszN NGj4OWNUSU6JRWK=
KP-N-YS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\PTWM2OD1zLkG2NlM3KM7:TR?= MYDTRW5ITVJ?
CAL-120 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nRcGlEPTB;MT6xOlQzQSEQvF2= M1zOW3NCVkeHUh?=
SBC-1 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT5VYFTUUN3ME2xMlE6ODV|IN88US=> MW\TRW5ITVJ?
C32 M{GzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HlOmlEPTB;MT6xPVA5QCEQvF2= NUfYVpJ3W0GQR1XS
HCC2157 NXvkeJBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwMUm0PVQh|ryP MVfTRW5ITVJ?
COLO-792 NILEe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33xcmlEPTB;MT6yNFA4OSEQvF2= M4[yenNCVkeHUh?=
ES7 NVXs[49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfpTWM2OD1zLkK3PVUyKM7:TR?= M2m1enNCVkeHUh?=
HEL NF7QbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu3TWM2OD1zLkOxNFI6KM7:TR?= M1H2XHNCVkeHUh?=
ES4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXWVoZKSzVyPUGuN|Q6QThizszN M{DOOHNCVkeHUh?=
NCI-SNU-1 NV7RfphPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwM{[1OVUh|ryP M1HieXNCVkeHUh?=
MDA-MB-415 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DxcmlEPTB;MT6zPFg2KM7:TR?= M4m3NXNCVkeHUh?=
NCI-H2342 NHOxbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rBeWlEPTB;MT60NFI3QSEQvF2= Mk\CV2FPT0WU
NB69 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorjTWM2OD1zLkS2NlcyKM7:TR?= M3LvWnNCVkeHUh?=
D-247MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXLcHJKSzVyPUGuOVEyOjJizszN MYDTRW5ITVJ?
SCC-4 M1XDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzCTWM2OD1zLkW5PFg4KM7:TR?= MnizV2FPT0WU
HuH-7 MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rOWGlEPTB;MT62O|I6OyEQvF2= NGfkd4tUSU6JRWK=
A388 NHXGRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fxXmlEPTB;MT62PFczPCEQvF2= NGPyTW1USU6JRWK=
Calu-3 NIjLZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXQTWM2OD1zLkewOlk4KM7:TR?= MXvTRW5ITVJ?
NCI-H1648 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M160TmlEPTB;MT63NVQyQCEQvF2= NXHyXoNnW0GQR1XS
NCI-H2052 M{fxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTZTWM2OD1zLkeyNlAyKM7:TR?= M2fp[3NCVkeHUh?=
Ramos-2G6-4C10 NWS5Oo9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwN{O2OVYh|ryP M1q2UnNCVkeHUh?=
DEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjNTWM2OD1zLke0OlkzKM7:TR?= NVyxbGZNW0GQR1XS
SNU-423 M4\i[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TWVWlEPTB;MT63PFE2PyEQvF2= NYjiNIdzW0GQR1XS
COR-L23 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj3TWM2OD1zLke5PFc1KM7:TR?= M3fDZnNCVkeHUh?=
OMC-1 M3L3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHyTWM2OD1zLki2NFE3KM7:TR?= NFjaXFlUSU6JRWK=
EW-11 NWDGV2V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwOUW2OVch|ryP NXftW5V{W0GQR1XS
HSC-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\NWY5KSzVyPUGuPVY{PjVizszN NFnG[YtUSU6JRWK=
MLMA NFL6TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T3[WlEPTB;MT65OlY4PyEQvF2= MYfTRW5ITVJ?
RCM-1 M2PtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfWW5NTUUN3ME2yMlAxOzl7IN88US=> MWDTRW5ITVJ?
MFE-280 MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLTZ2g6UUN3ME2yMlAzQDR6IN88US=> NYfST3VRW0GQR1XS
ES8 NIT6eWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLtTWM2OD1{LkK1OFcyKM7:TR?= MXrTRW5ITVJ?
TE-11 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV25Und7UUN3ME2yMlI6PDd|IN88US=> M2noTnNCVkeHUh?=
HuO-3N1 M3TGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X0NGlEPTB;Mj60PFc5KM7:TR?= NUnYdVM6W0GQR1XS
MHH-NB-11 NYW1UVRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[yfmlEPTB;Mj61NVE2QCEQvF2= MmD2V2FPT0WU
TGBC11TKB MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJwNUe2PFEh|ryP NVu5VnROW0GQR1XS
HOP-92 NYXL[29wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7oTWM2OD1{LkW4O|Q{KM7:TR?= M4Wz[3NCVkeHUh?=
IGR-1 MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\uXW9KSzVyPUKuOlIxOzVizszN M{TYc3NCVkeHUh?=
GOTO NFn5PItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrsWGNZUUN3ME2yMlY2Ozd5IN88US=> NIj5[ZBUSU6JRWK=
NCI-H1650 M4i1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{exTmlEPTB;Mj63NlIyPSEQvF2= Mlr3V2FPT0WU
NCI-H1581 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\hTWM2OD1{Lke5OlgyKM7:TR?= NV;wTJJiW0GQR1XS
NCI-H2405 NFPpTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3hUYNOUUN3ME2yMlgzPzh{IN88US=> NUTxUIpGW0GQR1XS
U-118-MG M2HIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwOU[0PVEh|ryP Ml;LV2FPT0WU
DoTc2-4510 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOycnVjUUN3ME2zMlAyPDF5IN88US=> MVPTRW5ITVJ?
NCI-H596 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;pbmlEPTB;Mz6wOFk6PyEQvF2= M3PrXXNCVkeHUh?=
MPP-89 NGHuNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK5RnhNUUN3ME2zMlA2PjZ4IN88US=> M1LucXNCVkeHUh?=
GCIY M2DnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fxNGlEPTB;Mz6yNFQ6OSEQvF2= Mn;5V2FPT0WU
SW626 NYfPZ3MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNwMkS1OFMh|ryP M4\xdXNCVkeHUh?=
OCI-AML2 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTJUW5nUUN3ME2zMlMyOjd{IN88US=> NI\hUllUSU6JRWK=
NBsusSR M{HT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwM{S5N|gh|ryP MV3TRW5ITVJ?
AN3-CA M3nrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTNwNESyN|gh|ryP M2HqRnNCVkeHUh?=
EFM-19 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjIWpZxUUN3ME2zMlQ5OzN7IN88US=> NVnhcGFSW0GQR1XS
RVH-421 NYHWc2hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPGTWM2OD1|LkW2PFc4KM7:TR?= MnXTV2FPT0WU
5637 NYDXW5ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NICxb|ZKSzVyPUOuOlEyODNizszN NGrHWIhUSU6JRWK=
PANC-08-13 M4XFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPSTWM2OD1|Lk[zOFczKM7:TR?= NWi3d3V6W0GQR1XS
H9 M2\HU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLwTWM2OD1|Lk[3NVQ1KM7:TR?= MUjTRW5ITVJ?
KARPAS-299 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjVU2JuUUN3ME2zMlY4OzZzIN88US=> NUOwbpV7W0GQR1XS
TE-5 NYfIVpppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDSTWM2OD1|LkewO|A6KM7:TR?= NH\aZWtUSU6JRWK=
NOS-1 NGLObXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjzd4lKSzVyPUOuO|k5OzRizszN M4jNbnNCVkeHUh?=
HH NXjNTHE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPXdIxIUUN3ME2zMlg{QDZ6IN88US=> Mmr4V2FPT0WU
769-P NI\uWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPoTWM2OD1|Lki5OVEh|ryP MmroV2FPT0WU
CHP-212 M3\xUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfuTWM2OD1|LkmyOVQ6KM7:TR?= M2jOPXNCVkeHUh?=
NCI-H82 MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLETWM2OD1|Lkm1PVM3KM7:TR?= MYjTRW5ITVJ?
Mo-T NGHVTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPUTm5KSzVyPUSuNFQ{OTJizszN MlzPV2FPT0WU
BB65-RCC Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLLTWM2OD12LkC0N|k6KM7:TR?= NHXPR2JUSU6JRWK=
SW1990 NFzzNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\WVJhKSzVyPUSuNFU6ODhizszN MULTRW5ITVJ?
LK-2 M{C5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTRwMUGyPVMh|ryP NYrPdYpNW0GQR1XS
ES5 M{\DTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrLb3NKSzVyPUSuNVM6QDVizszN Mmq0V2FPT0WU
JVM-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK5PYlNUUN3ME20MlE5OjJ{IN88US=> NU[2eW1EW0GQR1XS
RPMI-7951 M3;oWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkexTWM2OD12LkKyOFE{KM7:TR?= MmfXV2FPT0WU
Calu-6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml34TWM2OD12LkK3PFgyKM7:TR?= NHHvemZUSU6JRWK=
LC-2-ad MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;ISpNKSzVyPUSuNlk2PjhizszN NUfiNFRPW0GQR1XS
SW954 MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;0XIpKSzVyPUSuNlk3PiEQvF2= MXLTRW5ITVJ?
H-EMC-SS NVe0UJpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPDT3BKSzVyPUSuN|E5OzFizszN MnnEV2FPT0WU
ES3 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\icmlEPTB;ND6zOVQ1OSEQvF2= MlzFV2FPT0WU
no-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXDfIxsUUN3ME20MlM2PTV2IN88US=> MmHCV2FPT0WU
LAN-6 NH\VZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHwTWM2OD12LkS1NVg6KM7:TR?= M3L4d3NCVkeHUh?=
FTC-133 NF;wZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwNUO5OUDPxE1? M2PkWHNCVkeHUh?=
8505C NWr1b3pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTRwNUSyN{DPxE1? NH[4OnFUSU6JRWK=
SW620 NFfs[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fIfWlEPTB;ND61O|A2PyEQvF2= MUPTRW5ITVJ?
BCPAP NUnl[|FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL4VYNKSzVyPUSuOlM1QDFizszN NH;BTIJUSU6JRWK=
SK-LU-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTRwNk[wPFkh|ryP MYLTRW5ITVJ?
NCI-H1623 NYPSTmlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTRwN{CyNlgh|ryP MlvvV2FPT0WU
C2BBe1 NXjZe|NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\Td3FKSzVyPUSuO|QxODhizszN NI\nZ|lUSU6JRWK=
GP5d MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTRwN{izPFgh|ryP NUHielBjW0GQR1XS
NB6 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjl[YlKSzVyPUSuPFYzODRizszN MWnTRW5ITVJ?
MDA-MB-157 M3fKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPofHBbUUN3ME20Mlg5PzZizszN MnPxV2FPT0WU
UMC-11 NIm0WoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO1fYZIUUN3ME20Mlg5QTZ2IN88US=> M{jBUXNCVkeHUh?=
HCC1419 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTRwOUCwOlMh|ryP M1HufnNCVkeHUh?=
NCI-H2029 M{OxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrnNWpbUUN3ME20Mlk1OTh3IN88US=> NUHIdmFlW0GQR1XS
LXF-289 M3uwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTVwMEO3NVkh|ryP MUTTRW5ITVJ?
KINGS-1 M2qwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX5OXJpUUN3ME21MlA4PzR2IN88US=> Mnm5V2FPT0WU
HD-MY-Z MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf6O3VKSzVyPUWuNlM6PjlizszN NYmxVGc2W0GQR1XS
ESS-1 M36xTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTpflhKSzVyPUWuNlU2QTdizszN NEfpTWtUSU6JRWK=
GI-1 NGDROpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HhU2lEPTB;NT6yO|kzPiEQvF2= MkPhV2FPT0WU
RPMI-2650 NIXYO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTySVF5UUN3ME21MlM3OTZizszN MX7TRW5ITVJ?
IA-LM M3\UUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L1XGlEPTB;NT6zPVg4OSEQvF2= NYLuWJZKW0GQR1XS
KP-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1POSmlEPTB;NT60OlM{PCEQvF2= NEXDSHhUSU6JRWK=
G-402 NIriclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjaOoVKSzVyPUWuOVE5PjVizszN MXrTRW5ITVJ?
OS-RC-2 NFvWUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojYTWM2OD13LkWyOlA1KM7:TR?= NYr0cotNW0GQR1XS
NCI-H1155 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PLcGlEPTB;NT61OFk2PSEQvF2= MWHTRW5ITVJ?
OE19 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3eyUWlEPTB;NT62PFYzPCEQvF2= M330cnNCVkeHUh?=
U-2-OS NH;uc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj5[YxvUUN3ME21Mlg6ODF|IN88US=> NVrUeZV{W0GQR1XS
SCC-15 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTVwOUO2OlIh|ryP NH[xeFJUSU6JRWK=
NCI-H630 MkLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTVwOUm0NFQh|ryP MVvTRW5ITVJ?
PFSK-1 M4nKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq3bVVtUUN3ME22MlA2OjV7IN88US=> NVXOdmh1W0GQR1XS
NCI-H1770 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnoS5dKSzVyPU[uNlA5PzRizszN Mki4V2FPT0WU
SK-MEL-3 NHHCZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTZwNEK5NVUh|ryP NVfQPJhDW0GQR1XS
LB1047-RCC NIrteFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu4TlNKSzVyPU[uOFc3OjVizszN NHPtXHJUSU6JRWK=
NCI-H446 NXrwc4ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXDZY9vUUN3ME22MlYzQTJ3IN88US=> NYO2foVFW0GQR1XS
SW780 NXrX[FlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH2VplFUUN3ME22MlcxOTh3IN88US=> NV3C[oxbW0GQR1XS
NEC8 NGfBRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DXfWlEPTB;Nj63OlY{KM7:TR?= MnG5V2FPT0WU
NOMO-1 MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZwN{ixNVEh|ryP MkTWV2FPT0WU
COLO-668 NFP0VFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfCV2ppUUN3ME22Mlg1Ozh5IN88US=> NX7EcpNOW0GQR1XS
MC116 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvpTWM2OD14LkmzPFk4KM7:TR?= NIjZN2FUSU6JRWK=
HCC1937 M170[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TYOmlEPTB;Nj65PVI2OSEQvF2= NEnNV|lUSU6JRWK=
NCI-N87 NVe5Zlh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m0OmlEPTB;Nz6xPVI6OyEQvF2= MYrTRW5ITVJ?
COLO-320-HSR MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rsb2lEPTB;Nz6yNlc{QCEQvF2= M{nBVHNCVkeHUh?=
HCC1806 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnLZnBKSzVyPUeuNlYxPDRizszN NGq5Z5JUSU6JRWK=
OVCAR-3 NHvyU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTx[FBKSzVyPUeuN|MxOzhizszN MXHTRW5ITVJ?
NUGC-3 NV\NdWJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S2V2lEPTB;Nz6zPVY6PCEQvF2= M2TRZ3NCVkeHUh?=
SW1783 NH24UGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLFdpFKSzVyPUeuOFMyPzVizszN NXjocmhUW0GQR1XS
GCT NGDGcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDvPZdKSzVyPUeuOVY6ODZizszN NVr1[mxZW0GQR1XS
NCI-H2126 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3wOo9KSzVyPUeuO|M3OjVizszN NUTOc41lW0GQR1XS
MEL-HO NY\yWZlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFSxUGpKSzVyPUeuO|cxPTRizszN Mo\TV2FPT0WU
CAPAN-1 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HUWGlEPTB;Nz63O|M2PyEQvF2= NUj6Zm9sW0GQR1XS
SW756 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPYXJI5UUN3ME23Mlc5OzN|IN88US=> MnX4V2FPT0WU
SKG-IIIa Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTdwOEG4PVIh|ryP NGHYeZJUSU6JRWK=
HCE-T NIfZbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PkcWlEPTB;Nz64O|c5OyEQvF2= NUnrWXNIW0GQR1XS
Ca-Ski MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTdwOUmzPFMh|ryP M4C2cnNCVkeHUh?=
COLO-684 NVLiW|FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLqS3pKSzVyPUiuNFE5OThizszN NGrleoFUSU6JRWK=
KYSE-70 M3LUeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfPW45KSzVyPUiuNFc4OjlizszN NEfITG1USU6JRWK=
TI-73 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLuTWM2OD16LkK1PFUyKM7:TR?= M3TPSXNCVkeHUh?=
BT-20 NUe2OZNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXNe3llUUN3ME24MlI3ODV{IN88US=> NHn1UlRUSU6JRWK=
MHH-ES-1 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KR4tyUUN3ME24MlUyQDN2IN88US=> MXjTRW5ITVJ?
TE-12 MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjBSmhKSzVyPUiuOVk6OzFizszN NGPsdVdUSU6JRWK=
YH-13 MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzE[ZByUUN3ME24MlYyODB6IN88US=> MW\TRW5ITVJ?
SF126 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRThwOEO4OlUh|ryP M1O1ZnNCVkeHUh?=
J82 NInHUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRThwOUCwN|gh|ryP Mm\jV2FPT0WU
RCC10RGB M3izSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXrTWM2OD16Lkm5OVYyKM7:TR?= M1jSNXNCVkeHUh?=
SK-UT-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTlwMES5OFUh|ryP MkDHV2FPT0WU
LB2241-RCC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH2TWM2OD17LkG5NVM4KM7:TR?= NEHUbJZUSU6JRWK=
LB996-RCC M2ruWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;LOWlKSzVyPUmuNVk5QSEQvF2= MoLwV2FPT0WU
EPLC-272H NU\y[lZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTlwM{e2OVch|ryP NX7v[GtHW0GQR1XS
CTV-1 M{mzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTlwNU[1N|Ih|ryP MmLIV2FPT0WU
HSC-2 MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O2bGlEPTB;OT61O|U2KM7:TR?= MkTFV2FPT0WU
SK-MEL-28 NFHPRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPmTWM2OD17Lk[xPFk{KM7:TR?= MoTMV2FPT0WU
MMAC-SF NVrySYNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTlwNki3OUDPxE1? MV7TRW5ITVJ?
CP50-MEL-B M33Z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHTTWM2OD17Lke1O|gzKM7:TR?= NWLBNXZ3W0GQR1XS
HT-1080 M1rXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm5[WFKSzVyPUmuO|c4OzlizszN M3TIeHNCVkeHUh?=
HEC-1 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf3TWM2OD1zMD6zN|UzKM7:TR?= NIKwfINUSU6JRWK=
AGS NGXNNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[3TWM2OD1zMD6zO|Qh|ryP NE[wTXFUSU6JRWK=
GAMG MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jl[WlEPTB;MUCuOVE3OiEQvF2= NYjp[WlCW0GQR1XS
SW48 M1:yPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvGTWM2OD1zMD61NVg6KM7:TR?= NUPVT4E{W0GQR1XS
U031 NWXCNFM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ixbmlEPTB;MUCuOVkxQCEQvF2= M{TVWnNCVkeHUh?=
OVCAR-5 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H3ZmlEPTB;MUCuOlQzQSEQvF2= M3vXUXNCVkeHUh?=
SF295 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFyLk[3NFQh|ryP MkfUV2FPT0WU
BHT-101 M1LoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFyLkexO|ch|ryP NV\4NXBPW0GQR1XS
VMRC-RCZ MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LyVGlEPTB;MUGuN|IxOSEQvF2= NWDjbItLW0GQR1XS
ACHN NHTWR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ntemlEPTB;MUGuOFIyOSEQvF2= MknUV2FPT0WU
NCI-H526 M3\lSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXWPVVWUUN3ME2xNU42ODR|IN88US=> M3vzcHNCVkeHUh?=
MN-60 M4DCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TTcGlEPTB;MUGuOVM6KM7:TR?= MV;TRW5ITVJ?
NCI-H2291 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW1TWM2OD1zMT61OFY3KM7:TR?= NFe0UohUSU6JRWK=
SCC-25 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX4SHFKSzVyPUGxMlc2PTZizszN MUfTRW5ITVJ?
SK-MEL-2 M4i2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XO[2lEPTB;MUGuO|Y{PyEQvF2= M4HaTXNCVkeHUh?=
SN12C NVXZWYRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf0TWM2OD1zMT65N|U2KM7:TR?= M135SXNCVkeHUh?=
NCI-H69 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vWVGlEPTB;MUKuOFI{PCEQvF2= Mn7IV2FPT0WU
ME-180 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vhb2lEPTB;MUKuO|A2PCEQvF2= NWHB[4ZqW0GQR1XS
MC-IXC NHK4fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLsTWM2OD1zMj63OVE5KM7:TR?= MXjTRW5ITVJ?
NCI-H2347 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Px[mlEPTB;MUKuO|YyPCEQvF2= NX;zWGR{W0GQR1XS
M059J NIfpRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrNfVBKSzVyPUGyMlc4OjdizszN MnXQV2FPT0WU
A2058 NVfM[Gk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF{Lki2PFEh|ryP MlnMV2FPT0WU
VA-ES-BJ NYXxSGFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPFfGpKSzVyPUGyMlg4QDVizszN M1vQPXNCVkeHUh?=
Ca9-22 M1L0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;kTWM2OD1zMj65OFUyKM7:TR?= MYPTRW5ITVJ?
KNS-42 NEnYfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XYNWlEPTB;MUKuPVk5PCEQvF2= M3L4OnNCVkeHUh?=
LoVo M17kVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XOOmlEPTB;MUOuNlMyOyEQvF2= NIP1fJlUSU6JRWK=
AM-38 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L1fWlEPTB;MUOuNlU3PiEQvF2= NFf6bVJUSU6JRWK=
NB5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF|LkO3OVIh|ryP NWrVV45pW0GQR1XS
L-363 MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTTTWM2OD1zMz60NFM{KM7:TR?= M13PZnNCVkeHUh?=
SK-MEL-30 M3TMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjCU4FOUUN3ME2xOE4xPjR3IN88US=> Mo[zV2FPT0WU
NCI-H1563 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYmwcHl7UUN3ME2xOE43ODN7IN88US=> M3q1Z3NCVkeHUh?=
NCI-H2228 NW\LNYxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF2Lk[wO|ch|ryP MVvTRW5ITVJ?
MFM-223 NWXnflJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPJRnNKSzVyPUG1MlE5OTNizszN MXXTRW5ITVJ?
LB831-BLC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjhTWM2OD1zNT6yO|Y4KM7:TR?= M{HHOHNCVkeHUh?=
SW872 NXS4VpZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrhcoxKSzVyPUG1MlMxQDZizszN MV\TRW5ITVJ?
NCI-H522 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPjTWM2OD1zNT6zN|A3KM7:TR?= MUHTRW5ITVJ?
EW-1 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnSdHpKSzVyPUG1MlU1PjJizszN NV7YRWR6W0GQR1XS
HN MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLk[VBKSzVyPUG1MlU6PDJizszN M1ThSXNCVkeHUh?=
SW837 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLiPGZKSzVyPUG1Mlc5PDdizszN MXjTRW5ITVJ?
SCC-9 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzOTWM2OD1zNT64NVE1KM7:TR?= MX7TRW5ITVJ?
MKN7 NI\1coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS5[4ZoUUN3ME2xOU46PzN{IN88US=> M3K3SHNCVkeHUh?=
KYSE-410 NVLSVXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXpPGJKSzVyPUG2MlU6OSEQvF2= NV7GVIxlW0GQR1XS
SK-N-DZ NFvQVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3IN3NKSzVyPUG2MlYyOTZizszN NVe0c5YxW0GQR1XS
COR-L105 NHLHUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:w[GlEPTB;MU[uOlUzQCEQvF2= Ml7tV2FPT0WU
LB2518-MEL NY[2fnpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF4LkizPFkh|ryP MX;TRW5ITVJ?
OVCAR-4 MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlThTWM2OD1zNj64PFYzKM7:TR?= M4rPO3NCVkeHUh?=
TK10 NWfZe3JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjXV5lNUUN3ME2xOk46PDd|IN88US=> MXLTRW5ITVJ?
KNS-62 NILpRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P3ZmlEPTB;MU[uPVc4PyEQvF2= NHvqTm5USU6JRWK=
RPMI-8866 NVT6bFlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDGfotWUUN3ME2xO{4yPzN{IN88US=> NUK1VHNEW0GQR1XS
HuP-T4 NWHuXZVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHucpZSUUN3ME2xO{4zPDl3IN88US=> MYnTRW5ITVJ?
CGTH-W-1 NV3nSmx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:zRmlEPTB;MUeuOVIyQSEQvF2= MVXTRW5ITVJ?
T-24 M{XBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\FT2lEPTB;MUeuOVM1PyEQvF2= NY\6fFJuW0GQR1XS
HT-3 M{T0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[2W2tKSzVyPUG3MlU6OTRizszN NInpc|hUSU6JRWK=
KS-1 NYDLTWcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF5Lk[3N{DPxE1? NYHte4toW0GQR1XS
NCI-H1792 NVHGSoVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK5VY15UUN3ME2xO{44QThizszN NHftN4tUSU6JRWK=
ABC-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6xVIE2UUN3ME2xO{45OTRzIN88US=> NYnBS2MzW0GQR1XS
BPH-1 NHnBUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi3[2xQUUN3ME2xPE4yPjh3IN88US=> Ml3zV2FPT0WU
A431 M1HyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfvfoVKSzVyPUG4MlQyOjdizszN M3O2dXNCVkeHUh?=
T98G M{LSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLnTWM2OD1zOD61NVU4KM7:TR?= M4D0[XNCVkeHUh?=
BHY NUf5XFN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnNbVhMUUN3ME2xPE45PjlizszN MUHTRW5ITVJ?
Capan-2 M3zHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PZN2lEPTB;MUiuPVA4QCEQvF2= MWHTRW5ITVJ?
MDA-MB-175-VII NF7tcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHpTWM2OD1zOD65NlA6KM7:TR?= NU\kR3BJW0GQR1XS
CAL-27 M4Tsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv3TWM2OD1zOT6wOFg4KM7:TR?= MY\TRW5ITVJ?
AsPC-1 M3XNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF7Lki2OVch|ryP NGnKflVUSU6JRWK=
KU812 NX3xVodET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\ne28{UUN3ME2xPU46PTd|IN88US=> NXzwPG91W0GQR1XS
NCI-H441 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITrdXZKSzVyPUKwMlAxOSEQvF2= NGTqcXVUSU6JRWK=
Mewo NHHVbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnYenFKSzVyPUKwMlEzQDhizszN MnruV2FPT0WU
SK-MEL-24 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEGxT|ZKSzVyPUKwMlE1PzdizszN MUPTRW5ITVJ?
NCI-H727 M1Lj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;iS3VKSzVyPUKwMlI4ODRizszN M{XNSXNCVkeHUh?=
EKVX NV\zbm8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PXbmlEPTB;MkCuOlA3KM7:TR?= NH3FXmJUSU6JRWK=
RT-112 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC2TWM2OD1{MD62NVIzKM7:TR?= MYXTRW5ITVJ?
CAMA-1 M1K4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rXOmlEPTB;MkCuPVgxOyEQvF2= M4W4cnNCVkeHUh?=
SW900 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrTTWM2OD1{MT6wNVQ6KM7:TR?= NFPoSlZUSU6JRWK=
NCI-H23 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zLPGlEPTB;MkGuNVI4PyEQvF2= M2TCXnNCVkeHUh?=
SK-PN-DW NF\SRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGyZXdmUUN3ME2yNU4yPjR7IN88US=> M13y[XNCVkeHUh?=
BB30-HNC M4TpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH4WGZKSzVyPUKxMlI4PDVizszN M3HLc3NCVkeHUh?=
VM-CUB-1 NX7LUFZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DqOGlEPTB;MkGuN|U{PiEQvF2= MWLTRW5ITVJ?
IST-MEL1 NGDTZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\6S2tpUUN3ME2yNU4{Pjl{IN88US=> MkT2V2FPT0WU
CTB-1 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLDVIJTUUN3ME2yNU41PzV3IN88US=> M1OxR3NCVkeHUh?=
LCLC-103H NWfJWpB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLWR4l1UUN3ME2yNk4yPTh{IN88US=> MYXTRW5ITVJ?
PANC-03-27 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGwO5BKSzVyPUKyMlUyPjlizszN NVPxOXBJW0GQR1XS
HTC-C3 M{DnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TtXGlEPTB;MkKuOVU2PSEQvF2= M1LvTXNCVkeHUh?=
TE-8 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T6[WlEPTB;MkOuNlU3PSEQvF2= MYDTRW5ITVJ?
NCI-H292 M17OXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJ3LkO1N|Yh|ryP NXfPXYRQW0GQR1XS
COLO-680N NFO5OWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jHXGlEPTB;MkWuOlMzQSEQvF2= NX\lco8zW0GQR1XS
KYSE-520 NHqwUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW2TWM2OD1{NT62OFQh|ryP NWnGU4U1W0GQR1XS
NB10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnnS3ZKSzVyPUK2MlMyOTdizszN NVjUNnFiW0GQR1XS
NCI-H661 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;TTWM2OD1{Nj60O|E{KM7:TR?= MnvCV2FPT0WU
GMS-10 M3Tzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK3T4dKSzVyPUK2Mlg3OzhizszN NEHNT5FUSU6JRWK=
NCI-H2122 MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ4Lkm5PVgh|ryP M4nmZnNCVkeHUh?=
OVCAR-8 NWfw[FdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qwemlEPTB;MkeuNFY{QCEQvF2= NULHZ5RTW0GQR1XS
DJM-1 NE[yVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvoN|RYUUN3ME2yO{4yPDV2IN88US=> Mo\yV2FPT0WU
UACC-893 M{L1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S5dGlEPTB;MkeuPVg4QCEQvF2= M{TmNHNCVkeHUh?=
C8166 M4\kfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:zTWM2OD1{OD62PVM5KM7:TR?= MVnTRW5ITVJ?
NCI-H1693 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfUTWM2OD1{OD62PVc2KM7:TR?= NHvNU4lUSU6JRWK=
TYK-nu NGPSV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K1TmlEPTB;M{CuNFM1PSEQvF2= M1njTHNCVkeHUh?=
SW1710 NXvI[IVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPjRW5KSzVyPUOwMlEzPiEQvF2= NWXMbGZlW0GQR1XS
A375 NYjPdZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn4cXVKSzVyPUOwMlMzPDNizszN MYfTRW5ITVJ?
HMV-II NWrzZnQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HQXGlEPTB;M{GuN|U6OiEQvF2= MnHxV2FPT0WU
NCI-H2087 MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX6U29DUUN3ME2zNU43OzV{IN88US=> NEHXV49USU6JRWK=
CAL-54 NEftRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNzLkeyOFEh|ryP NEDwOphUSU6JRWK=
HCC70 NXHHUpNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln4TWM2OD1|Mj6xN|g4KM7:TR?= M4nRUXNCVkeHUh?=
ES1 M{e0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN{LkOwOlIh|ryP MlvpV2FPT0WU
NCI-H1355 NUHrNWFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP2WWpQUUN3ME2zN{4zODRizszN M2jOSHNCVkeHUh?=
CFPAC-1 NEfNU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnzTWM2OD1|Mz6yN|MzKM7:TR?= NETsNZNUSU6JRWK=
MKN28 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTN|LkO4NFkh|ryP Moq2V2FPT0WU
HDLM-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvOTnpSUUN3ME2zN{43QTNzIN88US=> MVfTRW5ITVJ?
PANC-10-05 NUnQd4xXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN2LkGwNVQh|ryP M4j5WHNCVkeHUh?=
SAS M3jhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf5TWM2OD1|ND60OVY2KM7:TR?= NEnBSlVUSU6JRWK=
HCC1395 M{ewUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN2LkexPFYh|ryP MXXTRW5ITVJ?
8305C NFT4[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfXb2xKSzVyPUO1Mlg1OTVizszN MkTVV2FPT0WU
KM12 M3niSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN4Lke1OFch|ryP Mn\EV2FPT0WU
SW1116 NF3UVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXwTWM2OD1|Nz61PVkzKM7:TR?= NUf0colXW0GQR1XS
SK-MEL-1 NYq3ZoRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ntfmlEPTB;M{iuN|M5QSEQvF2= NYTXWXNEW0GQR1XS
HCC2218 NFTuRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTuWG9KSzVyPUO4MlY2OTlizszN NWrSVWs{W0GQR1XS
T84 M1\nTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnZfmtKSzVyPUO4Mlc1ODlizszN NUXSVnc1W0GQR1XS
ETK-1 M2fVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OzSWlEPTB;M{muNFIzKM7:TR?= MVfTRW5ITVJ?
COLO-800 NHjCVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnVTWM2OD1|OT6zPFY5KM7:TR?= NGi5T3lUSU6JRWK=
CAL-12T NITsNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjnTWM2OD1|OT61NlgyKM7:TR?= Mni2V2FPT0WU
ACN M3\QZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrtTWM2OD12MD60PVEyKM7:TR?= NX7wWVVzW0GQR1XS
SJSA-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DGdmlEPTB;NEGuNVU6PiEQvF2= MYPTRW5ITVJ?
PSN1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTRzLkG3OFkh|ryP NV:1O3lzW0GQR1XS
D-566MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LMOmlEPTB;NEGuNlA5PiEQvF2= NHLGVXRUSU6JRWK=
EGI-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlriTWM2OD12Mj60Nlgh|ryP MXLTRW5ITVJ?
A204 NUXtbmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTxVoxuUUN3ME20Nk43Ozh6IN88US=> M1zrbnNCVkeHUh?=
Saos-2 NGPCSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTR{LkizOlkh|ryP Ml;3V2FPT0WU
SNU-C2B MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTR|Lk[4O|gh|ryP NEXIOXhUSU6JRWK=
HLE MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PmN2lEPTB;NESuNFg2PiEQvF2= MoTMV2FPT0WU
SW1463 NHzUfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPB[YdKSzVyPUS0Mlk6PzFizszN MXPTRW5ITVJ?
DSH1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTR3LkCwN|Mh|ryP M1jm[3NCVkeHUh?=
MCF7 NHrKNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\FWY9KSzVyPUS1MlUxPTFizszN Mn3mV2FPT0WU
K5 NFHOSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSwNGluUUN3ME20OU46PDB3IN88US=> NFK0R|VUSU6JRWK=
NCI-H358 M1HxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3iTWM2OD12Nz6yNVUh|ryP MYfTRW5ITVJ?
NCI-H2030 NWrzXGJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrqR4tKSzVyPUS3MlI{PzRizszN NUnsfpVWW0GQR1XS
SW948 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP2PYNKSzVyPUS3MlQ3PCEQvF2= NVPieoJMW0GQR1XS
BALL-1 NF\PXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXVTWM2OD12Nz62NVY5KM7:TR?= MkPIV2FPT0WU
TE-9 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnSSWVKSzVyPUS3Mlk2QDFizszN MkTCV2FPT0WU
SK-N-FI MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTR6LkCzOVgh|ryP MoLvV2FPT0WU
KALS-1 NVW3epNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPiWmx5UUN3ME20PE4yOjh7IN88US=> MoPPV2FPT0WU
HO-1-N-1 M{H1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH0XVVKSzVyPUS4Mlc1PDVizszN MVzTRW5ITVJ?
NCI-H2452 NEPMeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fpcWlEPTB;NEmuNVE2OiEQvF2= M{SySXNCVkeHUh?=
OC-314 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfvXm5KSzVyPUS5MlY5OzRizszN MWXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; 

PubMed: 26811457     


(A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control.

caspase3 / cleaved caspase 3; 

PubMed: 24481442     


(b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa). 

26811457 24481442
Growth inhibition assay
Cell viability; 

PubMed: 25685063     


(C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.

25685063
In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Lung Small Cell Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Lung Small Cell Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID